Swiss biopharmaceutical company Opna Bio has dosed the first subject in a Phase I clinical trial of OPN-6602, an EP300/CBP bromodomain inhibitor designed to treat multiple myeloma.
The study aims to enrol up to 130 subjects with relapsed or refractory multiple myeloma at various trial sites across the US.
Go deeper with GlobalData
The first dose was administered at The START Center for Cancer Research in Grand Rapids, Michigan.
The open-label trial will evaluate the safety, tolerability, pharmacokinetics and early anti-tumour activity of OPN-6602, both as a standalone treatment and in combination with dexamethasone.
It plans to enrol 90 patients in a dose-escalation phase and an additional 40 in a dose-expansion phase.
The study is expected to be completed in the second half of 2026.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOPN-6602 is an oral small molecule designed to hinder the E1A binding protein (EP300) and CREB-binding protein (CBP), which are both involved in regulating genes that promote myeloma cell growth.
The asset has demonstrated significant anti-tumour effects in preclinical tests, with a 71% decline in tumour growth when used alone and more than 100% inhibition in combination treatments.
Opna Bio CEO Reinaldo Diaz said: “We are pleased to initiate clinical testing of OPN-6602, which has shown potent anti-tumour activity in multiple myeloma models as well as other cancers.”
Founded in 1998, Opna Bio focuses on discovering and developing therapies for various forms of cancer.
The company’s diverse pipeline includes a programme targeting the fragile-X mental retardation protein (FMRP) and other promising oncology assets.
In November 2022, Opna Bio secured $38m in a Series A funding round led by Longitude Capital and Northpond Ventures, with participation from Menlo Ventures.
The company has used these revenues to create fragile-X mental retardation protein (FMRP) inhibitors for cancer, as well as a wide portfolio of clinical and preclinical oncology activities purchased from Plexxikon.
